Walter M. Stadler to Maximum Tolerated Dose
This is a "connection" page, showing publications Walter M. Stadler has written about Maximum Tolerated Dose.
Connection Strength
0.417
-
Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349.
Score: 0.215
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.038
-
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016 Jan; 77(1):155-62.
Score: 0.031
-
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 07; 26(7):1459-64.
Score: 0.029
-
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
Score: 0.023
-
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
Score: 0.022
-
A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10.
Score: 0.021
-
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
Score: 0.019
-
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51.
Score: 0.017